REXALL SUNDOWN THIRD QUARTER NET SALES RISE 28.7%
This article was originally published in The Tan Sheet
Executive Summary
REXALL SUNDOWN THIRD QUARTER NET SALES RISE 28.7% to $30.9 mil., the company announced July 5. The vitamin/OTC company's sales to retailers advanced by 33% during the quarter, while mail order sales rose 9.5% and direct sales increased by 29.7%. Results for the quarter ended May 31 included net sales of $2 mil. for Pennex Labs, the company's OTC drug unit.